SE0202464D0 - Use of compounds - Google Patents

Use of compounds

Info

Publication number
SE0202464D0
SE0202464D0 SE0202464A SE0202464A SE0202464D0 SE 0202464 D0 SE0202464 D0 SE 0202464D0 SE 0202464 A SE0202464 A SE 0202464A SE 0202464 A SE0202464 A SE 0202464A SE 0202464 D0 SE0202464 D0 SE 0202464D0
Authority
SE
Sweden
Prior art keywords
diseases
driven
compounds
conditions
cell
Prior art date
Application number
SE0202464A
Other languages
Swedish (sv)
Inventor
Per-Olof Ericsson
Karin Kristensson
Pascalis Sideras
Peter Sjoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202464A priority Critical patent/SE0202464D0/en
Publication of SE0202464D0 publication Critical patent/SE0202464D0/en
Priority to PCT/SE2003/001274 priority patent/WO2004016270A1/en
Priority to AU2003251271A priority patent/AU2003251271A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the treatment of mast cell-driven or basophil-driven conditions or diseases by inhibiting the activity of Inducible T cell kinase (Itk). Particular conditions or diseases that may be treated include asthma, rhinitis, COPD.
SE0202464A 2002-08-14 2002-08-14 Use of compounds SE0202464D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
SE0202464A SE0202464D0 (en) 2002-08-14 2002-08-14 Use of compounds
PCT/SE2003/001274 WO2004016270A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES
AU2003251271A AU2003251271A1 (en) 2002-08-14 2003-08-13 USE OF Itk INHIBITORS FOR THE TREATMENT OF MAST CELL-DRIVEN OR BASOPHIL-DRIVEN DISEASES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202464A SE0202464D0 (en) 2002-08-14 2002-08-14 Use of compounds

Publications (1)

Publication Number Publication Date
SE0202464D0 true SE0202464D0 (en) 2002-08-14

Family

ID=20288752

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202464A SE0202464D0 (en) 2002-08-14 2002-08-14 Use of compounds

Country Status (3)

Country Link
AU (1) AU2003251271A1 (en)
SE (1) SE0202464D0 (en)
WO (1) WO2004016270A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102325A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103804381A (en) * 2012-11-06 2014-05-21 韩冰 Compound for treatment of ischemic brain damage and application thereof
CA2973773C (en) 2015-02-02 2023-10-17 Kancera Ab 2-phenyl-3h-imidazo[4,5-b]pyridine derivatives useful as inhibitors of mammalian tyrosine kinase ror1 activity
JP6891262B2 (en) 2016-07-11 2021-06-18 カンセラ・アーベー 2-Phenylimidazole [4,5-B] pyridine-7-amine derivative useful as an inhibitor of mammalian tyrosine kinase ROR1 activity
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102101A3 (en) * 1997-11-10 2002-11-28 Bristol Myers Squibb Co Protein tyrosine kinase inhibitor benzothiazole derivatives and pharmaceutical compositions containing them
ATE396978T1 (en) * 1999-10-07 2008-06-15 Amgen Inc TRIAZINE KINASE INHIBITORS
OA12514A (en) * 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
CA2433018A1 (en) * 2000-12-21 2002-06-27 Joel C. Barrish Thiazolyl inhibitors of tec family tyrosine kinases

Also Published As

Publication number Publication date
AU2003251271A1 (en) 2004-03-03
WO2004016270A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
NO20052928L (en) New chemical compounds
MX2009006267A (en) Dihydropyridine derivatives useful as protein kinase inhibitors.
JO2872B1 (en) New Compounds
TW200607513A (en) Certain chemical entities, compositions, and methods
ATE441418T1 (en) USE OF TREPROSTINIL TO IMPROVE KIDNEY FUNCTION
NO20072747L (en) Process for the preparation of indazole compounds
NO20064895L (en) 6,6-Bisyclic ring-substituted heterobicyclic protein kinase inhibitors
NO20082026L (en) Deazapurins useful as inhibitors of Janus kinases
EA200801372A1 (en) METHODS OF OBTAINING SUBSTITUTED PYRIMIDINES
NO20080675L (en) P38-Map kinase inhibitors and methods for their use
DK1543011T3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine H4 receptor ligands
HRP20020748A2 (en) Substituted beta-carbolines with ikb-kinase inhibiting activity
WO2007109045A8 (en) Heterocyclic organic compounds for the treatment of in particular melanoma
EA201100427A1 (en) HETEROCYCLIC KINASE INHIBITORS
TW200801008A (en) Protein kinase inhibitors
DE602006014540D1 (en) Pyrrolopyridinderivate als proteinkinaseinhibitoren
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
NO20054371L (en) Somatostatin-dopamine chimeric analogs
ATE510822T1 (en) POTASSIUM CHANNEL INHIBITORS
ATE547396T1 (en) DICYCLOALKYLCARBAMOYL UREAS AS GLUCOKINASE ACTIVATORS
TW200726763A (en) Novel compound
NO20080061L (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
MX2010000956A (en) Compounds which inhibit beta-secretase activity and methods of use thereof.
SE0202464D0 (en) Use of compounds
ATE410235T1 (en) TREATMENT OF BALLAST WATER